Kymera presents Phase 1b data for KT-621 STAT6 degrader in atopic dermatitis

• Kymera Therapeutics set late-breaking and featured conference presentations for Phase 1b BroADen trial data on KT-621, its oral STAT6 degrader, at Society for Investigative Dermatology annual meeting and American Thoracic Society Respiratory Innovation Summit on May 16, 2026.
• Results have already been reported previously, showing target engagement in blood and skin, consistent shifts in disease-related inflammatory signals, early signs of clinical activity, and a safety profile viewed as supportive of continued development.
• New analyses to be presented focus on skin biology, pointing to strong local target engagement and broad downstream effects aligned with improvement in atopic dermatitis measures.
• Company also plans to highlight early evidence suggesting potential benefit in asthma based on biomarker changes and patient-reported outcomes observed in atopic dermatitis patients with comorbid asthma.
• Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing, with readouts expected by mid-2027 and late 2027, positioning program for potential Phase 3 registration studies across multiple Type 2 inflammatory diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150700PRIMZONEFULLFEED9720868) on May 15, 2026, and is solely responsible for the information contained therein.